5Vote!
PR News Wire (Free subscription) | 11/02/2009
WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira...
+Vote!
Miami Herald (Free subscription) | 10/14/2009
Abbott Laboratories says it beat its own expectations in the third quarter as sales of its drug Humira continued to climb, as did sales of medical products and nutritional products for children.
5Vote!
Examiner (Free subscription) | 10/14/2009
Abbott Laboratories says it beat its own expectations in the third quarter as sales of its drug Humira continued to climb, as did sales of medical products and nutritional products for children.
5Vote!
San Fransisco Chronicle (Free subscription) | 10/14/2009
Abbott Laboratories says it beat its own expectations in the third quarter as sales of its drug Humira continued to climb, as did sales of medical products and nutritional products for children. The North Chicago company says strong sales of Humira, an... Sponsored Topics: Abbott Laboratories - Adalimumab - Nutrition - Business - Health
5Vote!
Seattle Post-Intelligencer (Free subscription) | 10/14/2009
ABBOTT PARK, Ill. -- Abbott Laboratories says it beat its own expectations in the third quarter as sales of its drug Humira continued to climb, as did sales of medical products and nutritional products for children.
9Vote!
Seattle Times (Free subscription) | 10/14/2009
Abbott Laboratories says it beat its own expectations in the third quarter as sales of its drug Humira continued to climb, as did sales of medical products and nutritional products for children.
5Vote!
Star Tribune (Free subscription) | 10/14/2009
Medical products revenue increased after Abbott bought eye care products maker Advanced Medical Optics in February. That deal contributed $263 million in revenue in the third quarter. Sales of molecular diagnostic products rose 15 percent to $82 million. Sales of stents also increased, but revenue from lab diagnostic products and diabetes care items decreased.
4Vote!
kansascity.com (Free subscription) | 10/14/2009
Abbott Laboratories says it beat its own expectations in the third quarter as sales of its drug Humira continued to climb, as did sales of medical products and nutritional products for children.
5Vote!
San Diego Union (Free subscription) | 10/14/2009
Abbott Laboratories says it beat its own expectations in the third quarter as sales of its drug Humira continued to climb, as did sales of medical products and nutritional products for children.
5Vote!
Chicago Tribune (Free subscription) | 10/15/2009
... Wall Street analysts' estimates.Abbott said sales of its blockbuster rheumatoid arthritis drug Humira, which also treats other autoimmune disorders, were up nearly 24 percent worldwide, to $1.5 billion. "That's really what investors are concerned about: What's the Humira growth rate?" First American Funds analyst Tim Nelson said. "I was looking for $1.3 billion, and they did $1.5...
5Vote!
Chicago Tribune (Free subscription) | 10/14/2009
... 3.5 percent to $7.76 billion.Abbott said its sales of the blockbuster rheumatoid arthritis drug Humira, which also treats other autoimmune disorders, were up nearly 24 percent worldwide to $1.5 billion, an increase of nearly 24 percent from the prior year. The company said those sales were ahead of analyst expectations."Abbott is performing well, generating higher-than-expected earnings...
3Vote!
back-report.com (Free subscription) | 10/07/2009
I suffer from Rheumatoid arthritis and have several medicatins, one of which is Humira. I have taken this for 6 months. Has anyone taken this medication and had improvement in [...]
